Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients

Résumé fourni par la source

As T cell-mediated immunotherapies are being explored as a treatment strategy for relapsed and refractory chronic lymphocytic leukemia (CLL), the study of autologous T cells in patients with CLL has intensified [ 1 , 2 ]. The repertoire of αβ T cell receptors (TRA/TRB repertoire) in CLL patients exhibits several abnormalities. These include skewing of TRBV gene usage, marked oligoclonal CD8 + T expansions and the existence of stereotyped TRB rearrangements that are shared by unrelated patients [ 3 , 4 , 5 ].

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.